Complex analysis of coagulation tests in patients undergoing the combination of hemostatic and antithrombotic therapy following large joint arthroplasty

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


Aim. To assess the dynamics of coagulation parameters and the influence of its initial values on the development of postoperative thrombohemorrhagic complications in male and female patients undergoing large joint arthroplasty and received combination hemostatic and anticoagulant therapy.

Methods. A retrospective analysis of the medical records (n=253) of patients with arthroplasty, were divided into two groups based on the time differences between prescription of hemostatic and anticoagulation therapy. The first group includes 145 patients (57.31%, 112 women and 33 men) with time differences ≤17 h, and the second group includes 108 patients (42.68%, 78 women and 30 men) with time differences 18–24 h. The dynamics of coagulation test results were analyzed, and the influence of its initial value on the risk of postoperative thrombosis or bleeding was assessed.

Results. Thrombohemorrhagic complications were recorded in 27 (10.67%) patients, of which 22 (81.48%) were observed in group 1. In the first group, thrombosis developed in regimens with tranexamic acid (p=0.038) with 2.2 times higher incidence than in group 2 (p=0.023). The risk of thrombosis of women in the group 1 was increased by an initially low level of international normalized ratio [relative risk (RR) 13.333, p=0.00032] and activated partial thromboplastin time (RR=5.8, p=0.037). The risk of bleeding in group 1 increased by an increasing preoperative ­level of activated partial thromboplastin time (RR=18, p=0.0012 and RR=28, p=0.00022, respectively) for all patients and by a decreasing fibrinogen level (RR=23.25, p=0.00065) and platelets count (RR=10.2, p=0.038) for women.

Conclusion. To minimize the risks of thrombosis and bleeding after arthroplasty, especially in patients with initial deviations of hemostasis parameters from the norm, and, in particular, when using tranexamic acid as a hemosta­tic agent, it is recommended to observe the time interval between hemostatic and anticoagulant pharmacothe­rapy for at least 18 hours.

Full Text

Restricted Access

About the authors

L S Golovko

Rostov State Medical University

Author for correspondence.

Russian Federation, Rostov-on-Don, Russia

A V Safronenko

Rostov State Medical University


Russian Federation, Rostov-on-Don, Russia

E V Gantsgorn

Rostov State Medical University


Russian Federation, Rostov-on-Don, Russia

N V Sukhorukova

Rostov State Medical University


Russian Federation, Rostov-on-Don, Russia

Y S Maklyakov

Rostov State Medical University


Russian Federation, Rostov-on-Don, Russia


  1. Leitner L., Türk S., Heidinger M. et al. Trends and economic impact of hip and knee arthroplasty in Central Europe: Findings from the Austrian National Database. Sci. Reports. 2018; 8 (1): 4707. doi: 10.1038/s41598-018-23266-w.
  2. Veber E.V., Vorontsova T.N., Bogopolskaya A.S., Bezgodkov Yu.A. Routing of adult patients with pathology of hip and knee joints. Sovremennye problemy nauki i obrazovaniya. 2017; (2): 94. (In Russ.)
  3. Oremus K. Tranexamic acid for the reduction of blood loss in total knee arthroplasty. Ann. Transl. Med. 2015; 3 (1): 40. doi: 10.3978/j.issn.2305-5839.2015.03.35.
  4. Novikov A.V., Shchedrina M.A., Karataeva D.S., Martyanov A.S. Early rehabilitation of elderly patients following knee arthroplasty. Trudnyy patsient. 2018; 16 (6): 42–45. (In Russ.)
  5. Nikolaev N.S., Bezlyud­naya N.V., Didichenko S.N., Kadyrova L.R. Experience of endoprothetics of joints and recommendations for perio­perative management. Prakticheskaya meditsina. 2014; (5): 92–96. (In Russ.)
  6. Bozhkova S.A., Kasimova A.R., Nakopia V.B., Kornilov N.N. Do we know all about prevention of venous thromboembolism after major orthopedic surgery? Travmatologiya i ortopediya Rossii. 2018; 24 (1): 129–143. (In Russ.) doi: 10.21823/2311-2905-2018-24-1-129-143.
  7. Ershov D.S., Kopenkin S.S., Skoroglyadov A.V. Prophylaxis and treatment of deep vein thrombosis of lower extremities at total hip replacement: a literature review. Vestnik Rossyskogo gosudarstvennogo meditsinskogo universiteta. 2015; (3): 14–19. (In Russ.)
  8. Ziatdinov B.G., Akhtyamov I.F., Sadykov R.I. Modern facilities of thromboembolic complications prevention at the replacement of lower extremities large joints. Prakticheskaya meditsina. 2015; (4-1): 66–70. (In Russ.)
  9. Nakopiya V.B., Kornilov N.N., Bozhkova S.A. et al. Hidden blood loss after total knee arthroplasty with complex thromboprophylaxis. Sovremennye problemy nauki i obrazovaniya. 2017; (6): 97. (In Russ.) doi: 10.17513/spno.27272.
  10. Huang F., Wu Y., Yin Z. et al. A systematic review and meta-analysis of the use of antifibrinolytic agents in total hip arthroplasty. Hip. Int. 2015; 25 (6): 502–509. doi: 10.5301/hipint.5000285.
  11. Dobrovol'skiy F. Expedience of the prophylactic use of tranexamic acid in surgical practice. Vestnik eks­trennoy meditsiny. 2017; (3): 83–87. (In Russ.)
  12. Kapadia B.H., Torre B.B., Ullman N. et al. Redu­cing perioperative blood loss with antifibrinolytics and antifibrinolytic-like agents for patients undergoing total hip and total knee arthroplasty. J. Orthop. 2019; 16 (6): 513–516. doi: 10.1016/j.jor.2019.06.025.
  13. Register of medicines of Russia. Encyclopedia of drugs. (access date: 19.03.2020). (In Russ.)
  14. Fraval A., Duncan S., Murray T. et al. OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. HIP International. 2019; 29 (3): 239–244. doi: 10.1177/1120700018780125.
  15. Hourlier H., Fennema P. Tranexamic acid use and risk of thrombosis in regular users of antithrombotics undergoing primary total knee arthroplasty: a prospective cohort study. Blood Transfus. 2018; 16 (1): 44–52. doi: 10.2450/2016.0160-16.
  16. Wang J.W., Chen B., Lin P.C. et al. The efficacy of combined use of Rivaroxaban and Tranexamic acid on blood conservation in minimally invasive total knee arthroplasty: a double-blind randomized, controlled ­trial. J. Arthroplasty. 2017; 32 (3): 801–806. doi: 10.1016/j.arth.2016.08.020.
  17. Karampinas P.K., Megaloikonomos P.D., Lampropoulou-Adamidou K. et al. Similar thromboprophylaxis with rivaroxaban and low molecular weight heparin but fewer hemorrhagic complications with combined intra-­articular and intravenous tranexamic acid in total knee arthroplasty. Eur. J. Orthop. Surg. Traumatol. 2019; 29: 455–460. doi: 10.1007/s00590-018-2307-7.
  18. Russian clini­cal guidelines “Prevention of Venous Thromboembolic Complications”. Travmatologiya i ortopediya Rossii. 2012; 1 (suppl.): 1–24. (In Russ.)
  19. Russian clinical guidelines for the diagnosis, treatment and prevention of Venous Thromboembolic Complications (VTE). Flebologiya. 2015; 9 (4-2): 1–52 (In Russ.)
  20. Antropova I.P., Shlykov I.L., Kuznetsova N.L. Hemostasis system after the knee endoprosthetics under antithrombotic prevention by Dabigatran direct thrombin inhibitor. Geniy ortopedii. 2011; (4): 90–96. (In Russ.)
  21. Golovko L.S., Safronenko A.V., Gantsgorn E.V., Sukhorukova N.V. Thrombohemorrhagic complications among patients after knee and hip arthroplasty on the background of joint therapy with hemostatic and anticoa­gulants. Uralskiy meditsinskiy zhurnal. 2020; (1): 47–52. (In Russ.) doi: 10.25694/URMJ.2020.01.09.

Supplementary files

Supplementary Files Action
Рис. 1. Динамика активированного частичного тромбопластинового времени (АЧТВ). Сплошной линией А обозначена динамика АЧТВ у женщин (n=190). Пунктирной линией Б обозначена динамика АЧТВ у мужчин (n=63)

Download (19KB) Indexing metadata
Рис. 2. Динамика фибриногена (Фг). Сплошной линией А обозначена динамика Фг у женщин (n=190). Пунк­тирной линией Б обозначена динамика Фг у мужчин (n=63)

Download (18KB) Indexing metadata
Рис. 3. Динамика международного нормализованного отношения (МНО). Сплошной линией А обозначена динамика МНО у женщин (n=190). Пунктирной линией Б обозначена динамика МНО у мужчин (n=63)

Download (19KB) Indexing metadata
Рис. 4. Динамика протромбинового времени (ПВ). Сплошной линией А обозначена динамика ПВ у женщин (n=190). Пунктирной линией Б обозначена динамика ПВ у мужчин (n=63)

Download (18KB) Indexing metadata
Рис. 5. Динамика тромбоцитов (Тц). Сплошной линией А обозначена динамика Тц у женщин (n=190). Пунктирной линией Б обозначена динамика Тц у мужчин (n=63)

Download (20KB) Indexing metadata



Abstract - 95

PDF (Russian) - 0




© 2020 Golovko L.S., Safronenko A.V., Gantsgorn E.V., Sukhorukova N.V., Maklyakov Y.S.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies